Cost-effectiveness of the ONCORAL Multidisciplinary Programme for the Management of Outpatients Taking Oral Anticancer Agents at Risk of Drug-related Event: Protocol for a Pragmatic Randomised Controlled Study

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 Feb 17

PMID 38367968

Authors

Laure Huot

Pascale Guerre

Guillaume Descotes

Anne-Gaelle Caffin

Chloe Herledan

Florence Ranchon

Catherine Rioufol

Affiliations

Soon will be listed here.

Abstract

Introduction: The development of oral anticancer agents (OAA) has profoundly changed cancer care, leading patients to manage their chemotherapy treatment on an outpatient basis. The prevention of iatrogenic effects of OAA remains a major concern, especially since their side effects are not less serious than those of intravenous chemotherapy. The ONCORAL programme was set up to secure the management of OAA in cancer patients followed at the Lyon University Hospital. This multidisciplinary programme involves hospital pharmacists, nurses, oncologists, and haematologists, as well as community health professionals. Given the economic stakes that this programme entails for the health system, a medico-economic study was designed.

Methods And Analysis: This is a prospective controlled study, with individual open-label randomisation. A total of 216 outpatients treated with OAA and at risk of developing a drug-related iatrogenic event, will be randomised (2:1) to undergo follow-up in the ONCORAL programme or usual care. The primary outcome will be the estimation of the incremental cost-effectiveness ratio (difference in total costs per quality adjusted life years gained) at 12 months between the two groups. The secondary outcomes will be evaluation of OAA management consequences (relative-dose intensity, adherence, adverse drug events, drug-drug interactions, and proven medication errors), evaluation of overall survival and cancer-related quality of life, and patient-reported outcomes in relation to the treatment. A budget impact analysis will be implemented. Patient and health professional satisfaction regarding the ONCORAL programme will be measured.

Ethics And Dissemination: Approval to conduct this study was obtained from an Ethics Committee () in October 2019, and from the French data protection agency (), according to the French Law. Trial results will be disseminated at clinical conferences and published in peer-reviewed journals.

Trial Registration: NCT03660670.

References

Ruiz M, Pardo A, Rejas J, Soto J, Villasante F, Aranguren J . Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q). Value Health. 2008; 11(5):913-26. DOI: 10.1111/j.1524-4733.2008.00323.x. View

Liu S, Kurzrock R . Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management. Semin Oncol. 2015; 42(6):863-75. DOI: 10.1053/j.seminoncol.2015.09.032. View

Liu G, Franssen E, Fitch M, Warner E . Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997; 15(1):110-5. DOI: 10.1200/JCO.1997.15.1.110. View

Sidani S, Doran D . Development and Validation of a Self-Care Ability Measure. Can J Nurs Res. 2018; 46(1):11-25. DOI: 10.1177/084456211404600103. View

ONeill V, Twelves C . Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002; 87(9):933-7. PMC: 2364332. DOI: 10.1038/sj.bjc.6600591. View

Rosenberg S, Petrie K, Stanton A, Ngo L, Finnerty E, Partridge A . Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review. J Natl Cancer Inst. 2020; 112(5):443-465. PMC: 7225676. DOI: 10.1093/jnci/djz244. View

Mathes T, Antoine S, Pieper D, Eikermann M . Adherence enhancing interventions for oral anticancer agents: a systematic review. Cancer Treat Rev. 2013; 40(1):102-8. DOI: 10.1016/j.ctrv.2013.07.004. View

Di Nitto M, Sollazzo F, Biagioli V, Pucciarelli G, Torino F, Alvaro R . Self-care behaviors in patients with cancer treated with oral anticancer agents: a systematic review. Support Care Cancer. 2022; 30(10):8465-8483. DOI: 10.1007/s00520-022-07166-4. View

Weinstein M, Torrance G, McGuire A . QALYs: the basics. Value Health. 2009; 12 Suppl 1:S5-9. DOI: 10.1111/j.1524-4733.2009.00515.x. View

10.

Hryniuk W, Bush H . The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984; 2(11):1281-8. DOI: 10.1200/JCO.1984.2.11.1281. View

11.

Pfeiffer P, Mortensen J, Bjerregaard B, Eckhoff L, Schonnemann K, Sandberg E . Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer. 2006; 42(16):2738-43. DOI: 10.1016/j.ejca.2006.06.027. View

12.

Shirotake S, Yasumizu Y, Ito K, Masunaga A, Ito Y, Miyazaki Y . Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016; 14(6):e575-e583. DOI: 10.1016/j.clgc.2016.03.014. View

13.

Andrade L, Ludwig K, Ramos Goni J, Oppe M, de Pouvourville G . A French Value Set for the EQ-5D-5L. Pharmacoeconomics. 2020; 38(4):413-425. PMC: 7080328. DOI: 10.1007/s40273-019-00876-4. View

14.

Drummond M, Weatherly H, Ferguson B . Economic evaluation of health interventions. BMJ. 2008; 337:a1204. DOI: 10.1136/bmj.a1204. View

15.

Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R . Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016; 10:1609-21. PMC: 5003561. DOI: 10.2147/PPA.S106629. View

16.

Zerbit J, Kroemer M, Fuchs B, Detroit M, Decroocq J, Vignon M . Pharmaceutical cancer care for haematology patients on oral anticancer drugs: Findings from an economic, clinical and organisational analysis. Eur J Cancer Care (Engl). 2022; 31(6):e13753. DOI: 10.1111/ecc.13753. View

17.

Clairet A, Boiteux-Jurain M, Curtit E, Jeannin M, Gerard B, Nerich V . Interaction between phytotherapy and oral anticancer agents: prospective study and literature review. Med Oncol. 2019; 36(5):45. DOI: 10.1007/s12032-019-1267-z. View

18.

Sivakumaran K, Ginex P, Waseem H, Belcher S, Lagler-Clark S, LeFebvre K . Domains of Structured Oral Anticancer Medication Programs: A Scoping Review. Oncol Nurs Forum. 2022; 49(4):296-306. PMC: 9303043. DOI: 10.1188/22.ONF.296-306. View

19.

Collomb B, Dubromel A, Caffin A, Herledan C, Larbre V, Baudouin A . Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program. Cancers (Basel). 2022; 14(3). PMC: 8833408. DOI: 10.3390/cancers14030660. View

20.

Liu S, Kurzrock R . Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat Rev. 2014; 40(7):883-91. DOI: 10.1016/j.ctrv.2014.05.003. View